These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

101 related articles for article (PubMed ID: 23671547)

  • 1. Factors associated with reduced efficacy of sitagliptin therapy: analysis of 93 patients with type 2 diabetes treated for 1.5 years or longer.
    Kanamori A; Matsuba I
    J Clin Med Res; 2013 Jun; 5(3):217-21. PubMed ID: 23671547
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Factor Analysis of Changes in Hemoglobin A1c After 12 Months of Sitagliptin Therapy in Patients With Type 2 Diabetes.
    Yuasa S; Sato K; Takai M; Ishikawa M; Umezawa S; Kubota A; Maeda H; Kanamori A; Miyakawa M; Tanaka Y; Terauchi Y; Matsuba I
    J Clin Med Res; 2016 Jun; 8(6):461-71. PubMed ID: 27222674
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Efficacy and Safety of Adding Sitagliptin in Type 2 Diabetes Patients on Insulin: Age-Stratified Comparison at One Year in the ASSIST-K Study.
    Takai M; Ishikawa M; Maeda H; Kanamori A; Kubota A; Amemiya H; Iizuka T; Iemitsu K; Iwasaki T; Uehara G; Umezawa S; Obana M; Kaneshige H; Kaneshiro M; Kawata T; Sasai N; Saito T; Takuma T; Takeda H; Tanaka K; Nakajima S; Hoshino K; Honda S; Machimura H; Matoba K; Minagawa F; Minami N; Miyairi Y; Mokubo A; Motomiya T; Waseda M; Miyakawa M; Terauchi Y; Tanaka Y; Matsuba I
    J Clin Med Res; 2019 May; 11(5):311-320. PubMed ID: 31019624
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Medium-Term Effect of Add-On Therapy with the DPP-4 Inhibitor, Sitagliptin, in Insulin-Treated Japanese Patients with Type 2 Diabetes Mellitus.
    Katsuno T; Ikeda H; Namba M
    Diabetes Ther; 2016 Jun; 7(2):309-20. PubMed ID: 27114254
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Efficacy and safety of sitagliptin monotherapy and combination therapy in Japanese type 2 diabetes patients.
    Kubota A; Maeda H; Kanamori A; Matoba K; Jin Y; Minagawa F; Obana M; Iemitsu K; Ito S; Amamiya H; Kaneshiro M; Takai M; Kaneshige H; Hoshino K; Ishikawa M; Minami N; Takuma T; Sasai N; Aoyagi S; Kawata T; Mokubo A; Takeda H; Honda S; Machimura H; Motomiya T; Waseda M; Naka Y; Tanaka Y; Terauchi Y; Matsuba I
    J Diabetes Investig; 2012 Dec; 3(6):503-9. PubMed ID: 24843615
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Efficacy and safety of the dipeptidyl peptidase-4 inhibitor, sitagliptin, in patients with type 2 diabetes mellitus inadequately controlled on glimepiride alone or on glimepiride and metformin.
    Hermansen K; Kipnes M; Luo E; Fanurik D; Khatami H; Stein P;
    Diabetes Obes Metab; 2007 Sep; 9(5):733-45. PubMed ID: 17593236
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Factors Predicting Therapeutic Efficacy of Combination Treatment With Sitagliptin and Insulin in Type 2 Diabetic Patients: The ASSIST-K Study.
    Ishikawa M; Takai M; Maeda H; Kanamori A; Kubota A; Amemiya H; Iizuka T; Iemitsu K; Iwasaki T; Uehara G; Umezawa S; Obana M; Kaneshige H; Kaneshiro M; Kawata T; Sasai N; Saito T; Takuma T; Takeda H; Tanaka K; Tsurui N; Nakajima S; Hoshino K; Honda S; Machimura H; Matoba K; Minagawa F; Minami N; Miyairi Y; Mokubo A; Motomiya T; Waseda M; Miyakawa M; Naka Y; Terauchi Y; Tanaka Y; Matsuba I
    J Clin Med Res; 2015 Aug; 7(8):607-12. PubMed ID: 26124906
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effects of 6-month sitagliptin treatment on glucose and lipid metabolism, blood pressure, body weight and renal function in type 2 diabetic patients: a chart-based analysis.
    Yanai H; Adachi H; Hamasaki H; Masui Y; Yoshikawa R; Moriyama S; Mishima S; Sako A
    J Clin Med Res; 2012 Aug; 4(4):251-8. PubMed ID: 22870172
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Efficacy and safety of sitagliptin in Japanese patients with type 2 diabetes.
    Ohmura H; Mita T; Taneda Y; Sugawara M; Funayama H; Matsuoka J; Watada H; Daida H;
    J Clin Med Res; 2015 Apr; 7(4):211-9. PubMed ID: 25699116
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Long-term efficacy of sitagliptin as either monotherapy or add-on therapy to metformin: improvement in glycemic control over 2 years in patients with type 2 diabetes.
    Katzeff HL; Williams-Herman D; Xu L; Golm GT; Wang H; Dong Q; Johnson JR; O'Neill EA; Kaufman KD; Engel SS; Goldstein BJ
    Curr Med Res Opin; 2015 Jun; 31(6):1071-7. PubMed ID: 25850968
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Comparative Efficacy of Adding Sitagliptin to Metformin, Sulfonylurea or Dual Therapy: A Propensity Score-Weighted Cohort Study.
    Mamza J; Mehta R; Donnelly R; Idris I
    Diabetes Ther; 2015 Jun; 6(2):213-26. PubMed ID: 26014844
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Efficacy and safety of the dipeptidyl peptidase-4 inhibitor sitagliptin compared with alpha-glucosidase inhibitor in Japanese patients with type 2 diabetes inadequately controlled on metformin or pioglitazone alone (Study for an Ultimate Combination Therapy to Control Diabetes with Sitagliptin-1): A multicenter, randomized, open-label, non-inferiority trial.
    Yokoh H; Kobayashi K; Sato Y; Takemoto M; Uchida D; Kanatsuka A; Kuribayashi N; Terano T; Hashimoto N; Sakurai K; Hanaoka H; Ishikawa K; Onishi S; Yokote K
    J Diabetes Investig; 2015 Mar; 6(2):182-91. PubMed ID: 25802726
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Efficacy of initial Basal-supported oral therapy with sitagliptin in untreated type 2 diabetes.
    Yoshioka K
    Diabetes Ther; 2013 Dec; 4(2):409-16. PubMed ID: 24127136
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Efficacy and safety in sitagliptin therapy for diabetes complicated by non-alcoholic fatty liver disease.
    Arase Y; Kawamura Y; Seko Y; Kobayashi M; Suzuki F; Suzuki Y; Akuta N; Kobayashi M; Sezaki H; Saito S; Hosaka T; Ikeda K; Kumada H; Ohmoto-Sekine Y; Hsieh SD; Amakawa K; Ogawa K; Matsumoto N; Iwao A; Tsuji H; Hara S; Mori Y; Okubo M; Sone H; Kobayashi T
    Hepatol Res; 2013 Nov; 43(11):1163-8. PubMed ID: 23489256
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Efficacy and safety of the dipeptidyl peptidase-4 inhibitor sitagliptin added to ongoing pioglitazone therapy in patients with type 2 diabetes: a 24-week, multicenter, randomized, double-blind, placebo-controlled, parallel-group study.
    Rosenstock J; Brazg R; Andryuk PJ; Lu K; Stein P;
    Clin Ther; 2006 Oct; 28(10):1556-68. PubMed ID: 17157112
    [TBL] [Abstract][Full Text] [Related]  

  • 16. PERsistent Sitagliptin treatment & Outcomes (PERS&O 2.0) study, long-term results: a real-world observation on DPP4-inhibitor effectiveness.
    Bossi AC; De Mori V; Galeone C; Bertola DP; Gaiti M; Balini A; Berzi D; Forloni F; Meregalli G; Turati F
    BMJ Open Diabetes Res Care; 2020 Sep; 8(1):. PubMed ID: 32900698
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A Randomized Controlled Trial of Vildagliptin Versus Alogliptin: Effective Switch From Sitagliptin in Patients With Type 2 Diabetes.
    Shigematsu E; Yamakawa T; Oba MS; Suzuki J; Nagakura J; Kadonosono K; Terauchi Y
    J Clin Med Res; 2017 Jul; 9(7):567-572. PubMed ID: 28611856
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Efficacy and safety of once-weekly semaglutide versus once-daily sitagliptin as an add-on to metformin, thiazolidinediones, or both, in patients with type 2 diabetes (SUSTAIN 2): a 56-week, double-blind, phase 3a, randomised trial.
    Ahrén B; Masmiquel L; Kumar H; Sargin M; Karsbøl JD; Jacobsen SH; Chow F
    Lancet Diabetes Endocrinol; 2017 May; 5(5):341-354. PubMed ID: 28385659
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The efficacy and safety of imeglimin as add-on therapy in patients with type 2 diabetes inadequately controlled with sitagliptin monotherapy.
    Fouqueray P; Pirags V; Diamant M; Schernthaner G; Lebovitz HE; Inzucchi SE; Bailey CJ
    Diabetes Care; 2014 Jul; 37(7):1924-30. PubMed ID: 24722500
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Sitagliptin, a dipeptidyl peptidase-4 inhibitor, decreases systolic blood pressure in Japanese hypertensive patients with type 2 diabetes.
    Ogawa S; Ishiki M; Nako K; Okamura M; Senda M; Mori T; Ito S
    Tohoku J Exp Med; 2011 Feb; 223(2):133-5. PubMed ID: 21304217
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.